Cancer Research Technology grants AstraZeneca an exclusive license to a key patent

Cancer Research Technology Limited has announced that AstraZeneca has licensed exclusive worldwide rights to a patent family relating to a nuclear receptor/co-activator binding motif.

Nuclear receptors require co-activator binding in order to activate gene transcription. Ligand-induced nuclear receptor conformational changes facilitate the recruitment of certain co-activators through the recognition of a specific motif contained within the co-activator protein. Prof. Malcolm Parker’s studies, funded by Cancer Research UK, identified this motif within the co-activator protein known as the LXXLL motif (where L is Leucine and X is any amino acid).

The nuclear receptor family represents a plethora of therapeutic targets for many clinical conditions. AstraZeneca’s research interests initially will focus on the area of respiratory and inflammation; however, broader application is possible across all of the company’s research areas. Targeting the nuclear receptor/co-activator interaction represents an alternative strategy for the inhibition of nuclear receptors.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough in aging research: Blocking IL-11 extends lifespan and improves health in mice